919 related articles for article (PubMed ID: 11507063)
21. Differential expression of matrilysin and cyclooxygenase-2 in intestinal and colorectal neoplasms.
Shattuck-Brandt RL; Lamps LW; Heppner Goss KJ; DuBois RN; Matrisian LM
Mol Carcinog; 1999 Mar; 24(3):177-87. PubMed ID: 10204802
[TBL] [Abstract][Full Text] [Related]
22. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2).
Oshima M; Dinchuk JE; Kargman SL; Oshima H; Hancock B; Kwong E; Trzaskos JM; Evans JF; Taketo MM
Cell; 1996 Nov; 87(5):803-9. PubMed ID: 8945508
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: lack of efficacy against nascent adenomatous polyps in the Apc(Min) mouse.
Ritland SR; Leighton JA; Hirsch RE; Morrow JD; Weaver AL; Gendler SJ
Clin Cancer Res; 1999 Apr; 5(4):855-63. PubMed ID: 10213222
[TBL] [Abstract][Full Text] [Related]
24. Morphological and molecular processes of polyp formation in Apc(delta716) knockout mice.
Oshima H; Oshima M; Kobayashi M; Tsutsumi M; Taketo MM
Cancer Res; 1997 May; 57(9):1644-9. PubMed ID: 9135000
[TBL] [Abstract][Full Text] [Related]
25. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice.
Chulada PC; Thompson MB; Mahler JF; Doyle CM; Gaul BW; Lee C; Tiano HF; Morham SG; Smithies O; Langenbach R
Cancer Res; 2000 Sep; 60(17):4705-8. PubMed ID: 10987272
[TBL] [Abstract][Full Text] [Related]
26. Mouse models for hereditary nonpolyposis colorectal cancer.
de Wind N; Dekker M; van Rossum A; van der Valk M; te Riele H
Cancer Res; 1998 Jan; 58(2):248-55. PubMed ID: 9443401
[TBL] [Abstract][Full Text] [Related]
27. Cyclooxygenase-2 inhibitors down-regulate osteopontin and Nr4A2-new therapeutic targets for colorectal cancers.
Zagani R; Hamzaoui N; Cacheux W; de Reyniès A; Terris B; Chaussade S; Romagnolo B; Perret C; Lamarque D
Gastroenterology; 2009 Oct; 137(4):1358-66.e1-3. PubMed ID: 19549529
[TBL] [Abstract][Full Text] [Related]
28. Cyclo-oxygenase 2 inhibitors: emerging roles in the gut.
Grover JK; Yadav S; Vats V; Joshi YK
Int J Colorectal Dis; 2003 Jul; 18(4):279-91. PubMed ID: 12774242
[TBL] [Abstract][Full Text] [Related]
29. COX-2 inhibition and prevention of cancer.
Giercksky KE
Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):821-33. PubMed ID: 11566043
[TBL] [Abstract][Full Text] [Related]
30. Subepithelial myofibroblasts express cyclooxygenase-2 in colorectal tubular adenomas.
Adegboyega PA; Ololade O; Saada J; Mifflin R; Di Mari JF; Powell DW
Clin Cancer Res; 2004 Sep; 10(17):5870-9. PubMed ID: 15355919
[TBL] [Abstract][Full Text] [Related]
31. Cyclooxygenase-2 expression in fibroblasts and endothelial cells of intestinal polyps.
Sonoshita M; Takaku K; Oshima M; Sugihara K; Taketo MM
Cancer Res; 2002 Dec; 62(23):6846-9. PubMed ID: 12460897
[TBL] [Abstract][Full Text] [Related]
32. The inducible prostaglandin biosynthetic enzyme, cyclooxygenase 2, is not mutated in patients with attenuated adenomatous polyposis coli.
Spirio LN; Dixon DA; Robertson J; Robertson M; Barrows J; Traer E; Burt RW; Leppert MF; White R; Prescott SM
Cancer Res; 1998 Nov; 58(21):4909-12. PubMed ID: 9809998
[TBL] [Abstract][Full Text] [Related]
33. Use of NSAIDs for the chemoprevention of colorectal cancer.
Herendeen JM; Lindley C
Ann Pharmacother; 2003 Nov; 37(11):1664-74. PubMed ID: 14565811
[TBL] [Abstract][Full Text] [Related]
34. Gene modulation by Cox-1 and Cox-2 specific inhibitors in human colorectal carcinoma cancer cells.
Bottone FG; Martinez JM; Alston-Mills B; Eling TE
Carcinogenesis; 2004 Mar; 25(3):349-57. PubMed ID: 14633654
[TBL] [Abstract][Full Text] [Related]
35. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis.
Kawamori T; Rao CV; Seibert K; Reddy BS
Cancer Res; 1998 Feb; 58(3):409-12. PubMed ID: 9458081
[TBL] [Abstract][Full Text] [Related]
36. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice.
Swamy MV; Patlolla JM; Steele VE; Kopelovich L; Reddy BS; Rao CV
Cancer Res; 2006 Jul; 66(14):7370-7. PubMed ID: 16849589
[TBL] [Abstract][Full Text] [Related]
37. Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis.
Belton OA; Duffy A; Toomey S; Fitzgerald DJ
Circulation; 2003 Dec; 108(24):3017-23. PubMed ID: 14638539
[TBL] [Abstract][Full Text] [Related]
38. No effects of Smad2 (madh2) null mutation on malignant progression of intestinal polyps in Apc(delta716) knockout mice.
Takaku K; Wrana JL; Robertson EJ; Taketo MM
Cancer Res; 2002 Aug; 62(16):4558-61. PubMed ID: 12183405
[TBL] [Abstract][Full Text] [Related]
39. COX-2, NSAIDs and human neoplasia. Part I: Colorectal neoplasms.
Nasir A; Fernandez PM; Chughtai OR; Kaiser HE
In Vivo; 2002; 16(6):501-9. PubMed ID: 12494894
[TBL] [Abstract][Full Text] [Related]
40. The potential for a selective cyclooxygenase-2 inhibitor in the prevention of liver metastasis in human colorectal cancer.
Yamauchi T; Watanabe M; Hasegawa H; Nishibori H; Ishii Y; Tatematsu H; Yamamoto K; Kubota T; Kitajima M
Anticancer Res; 2003; 23(1A):245-9. PubMed ID: 12680220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
